| Study |
Reference |
|
Broe (Controls unexposed, general pop), 2025
|
Broe Prescription Drugs in Pregnancy and Congenital Malformations: A Population-Based Safety Screening Study. Pharmacoepidemiol Drug Saf 2025; 34:e70211
|
|
Broe (Controls unexposed, sick), 2025
|
Broe Prescription Drugs in Pregnancy and Congenital Malformations: A Population-Based Safety Screening Study. Pharmacoepidemiol Drug Saf 2025; 34:e70211 Broe, A. Screening for associations between prescription drug use in pregnancy and risk of congenital malformations Pharmacoepidemiol. Drug Saf. 2020; 29:545-.
|
|
Cesta_Israel, 2024
|
Cesta Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med 2024; 184:144-152
|
|
Cesta_Nordic, 2024
|
Cesta Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med 2024; 184:144-152
|
|
Cesta_USA, 2024
|
Cesta Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med 2024; 184:144-152
|
|
Chou, 2025
|
Chou Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan. Diabetes Obes Metab 2025; :
|
|
Dao (Controls exposed to metformin/insulin), 2024
|
Dao Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open 2024; 14:e083550 Dao, K. Reproductive safety of glucagon-like peptide 1 receptor agonists (GLP1-RA) after maternal exposure in early pregnancy: A comparative ENTIS cohort study Swiss Med. Wkly 2024; 154:135S-.
|
|
Dao (Controls unexposed, sick), 2024
|
Dao Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open 2024; 14:e083550 Dao, K. Reproductive safety of glucagon-like peptide 1 receptor agonists (GLP1-RA) after maternal exposure in early pregnancy: A comparative ENTIS cohort study Swiss Med. Wkly 2024; 154:135S-.
|
|
Hanif, 2025
|
Hanif Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonist Use During the First Trimester in Pregnant Women With Type 2 Diabetes. Am J Cardiol 2025; 246:10-13
|
|
Kolding - Semaglutide (Controls exposed to insulin), 2025
|
Kolding Pregnancy Outcomes After Semaglutide Exposure. Basic Clin Pharmacol Toxicol 2025; 136:e70021
|
|
Kolding - Semaglutide (Controls unexposed, general pop), 2025
|
Kolding Pregnancy Outcomes After Semaglutide Exposure. Basic Clin Pharmacol Toxicol 2025; 136:e70021
|
|
Lewin, 2025
|
Lewin Glucagon-Like Peptide-1 Receptor Agonists among Pregnancies with Pregestational Diabetes and Its Relationship with Congenital Malformations. Am J Perinatol 2025; :
|
|
Maya, 2025
|
Maya Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation. JAMA 2025; :
|
|
Pondugula, 2025
|
Pondugula Gestational Weight Gain and Hypertensive Disorders of Pregnancy With Prepregnancy and Early Pregnancy Glucagon-Like Peptide-1 Receptor Agonist Exposure. Obstet Gynecol 2025; :
|
